Chief Legal Officer · Vera Therapeutics, Inc. (VERA)

Jason Carter

FY2024 is the first fiscal year CompBrief holds for Jason Carter as a named executive officer of Vera Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,649,923

Salary $58,750Stock awards $2,374,930Bonus $21,700

1st of 4 named executive officers at Vera Therapeutics by FY2024 total.

4 named officers on file for Vera Therapeutics, FY2024

Jason Carter’s pay file — $29

  • 1 fiscal year of pay, line by line
  • VERA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vera Therapeutics’s whole pay program stands against its peers

  • Vera Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VERA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jason Carter’s full pay file as a PDF — free

More than this page: up to 10 years of Jason’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jason Carter compensation by year

Vera Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Vera Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$58,750
Bonus$21,700
Stock awards$2,374,930
Option awards$3,194,543
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$5,649,923

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vera Therapeutics, Inc. DEF 14A filed April 3, 2025, accession 0001140361-25-012034, and prior-year filings.

How this page was built: the Vera Therapeutics, Inc. filed document, accession 0001140361-25-012034. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU53,000$2,241,370—
Option108,000—$44.81

Per the Outstanding Equity Awards at Fiscal Year-End table in Vera Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed April 3, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-11-21Sale—3,864$27.8249,136

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Vera Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Jason Carter · this pageChief Legal Officer$5,649,923
Marshall FordycePresident and Chief Executive Officer$5,648,201
Robert BrennerChief Medical Officer$4,445,802
Sean GrantChief Financial Officer$2,246,532

The full Vera Therapeutics compensation record

free company brief

This page is one person within Vera Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vera Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Carter's compensation dossier · One-time report. No refunds.